Stockreport

Caladrius Biosciences Completes Enrollment in Phase 2 ESCaPE-CMD Trial for Coronary Microvascular Dysfunction

Caladrius Biosciences, Inc.  (CLBS) 
Last caladrius biosciences, inc. earnings: 11/6 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: caladrius.com/investors/overview
PDF BASKING RIDGE, N.J., June 04, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development [Read more]